OncoDefender
OncoDefender-CRC is the world's first molecular diagnostic capable of accurately distinguishing between high-risk and low-risk Stage I/II colorectal cancer tumors, thereby predicting the risk of recurrence of cancer in these patients.
Patients identified by OncoDefender-CRC as having high recurrence risk are likely to benefit from more aggressive treatment options from the start. Independent studies have demonstrated a significant improvement in overall survival rates for high-risk Stage I and Stage II colorectal cancer patients receiving adjuvant therapy within 60 days following surgical resection of their tumor. No other currently available molecular diagnostic test approaches the performance capabilities of OncoDefender-CRC in this regard ยป
 Patients identified by OncoDefender-CRC at high-risk of cancer recurrence may benefit from adjuvant therapy or other more aggressive treatment options. |
 The OncoDefender-CRC test will help physicians make appropriate post-surgical decisions about the need for adjuvant therapy. |
|
 |
|
|
